Efgartigimod Promising for Rare Pediatric Disease With Few Treatment Options – Medscape
		
		
		
- Efgartigimod Promising for Rare Pediatric Disease With Few Treatment Options  Medscape
 
- Argenx pulls back curtain on Vyvgart trial win as part of mission to ensure ‘no MG patient is left behind’  Fierce Pharma
 
- Myasthenia Gravis Drug Shows Benefits in Wider Range of Patients  MedPage Today
 
- MGFA Session 2025: Vyvgart safe, effective in adolescents with gMG  Myasthenia Gravis News
 
- Efgartigimod Effective in Seronegative gMG, Obexelimab Meets Primary End Point, FDA Accepts NDA for Tau Tracer MK-6240  Neurology Live